Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162). The publication by Rajaratnam et al(1) is entitled "Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials." Results are reported from two clinical trials that demonstrate the sleep-promoting effects of tasimelteon, a novel circadian regulator that acts by resetting the body clock. The internal body clock is a complex molecular machinery that governs the rhythm of many body functions, the most well described of which is the sleep-wake cycle.

In the same issue of The Lancet, in an accompanying editorial, "Let there be sleep -- on time," Cardinali and Golombek(2) discuss the implications of the circadian regulatory and sleep-promoting effects of tasimelteon. They also point to the need for public health education and a move towards more effective agents that do not present the safety issues encountered with current sleep treatments.

The article by Rajaratnam et al(1) presents results from two clinical studies with more than 400 volunteers, who were asked to initiate sleep five hours before their usual bedtimes. Tasimelteon was shown to reset the molecular machinery of the circadian clock and restore the sleep-wake cycle by improving both the ability to initiate and to maintain sleep as compared to placebo-treated patients.

The body's circadian clock plays significant roles in regulating sleep, mood as well as cardiovascular and metabolic processes.(3)(4) Circadian rhythm sleep disorders include insomnia associated with shift work (overnigh
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the global leader ... announced that Robert A. Ingram has retired from ... ardent champion for innovation in the lifesciences industry, and it ... board as we pursue our focused innovation strategy," said ... provided a valuable perspective to our board, drawing on his ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Results from Gene Identification Studies Presented at ASCO Support, ... ... REDWOOD CITY, Calif., May 31 Genomic Health,Inc. (Nasdaq: GHDX ... of two separate studies presented at the annual,meeting of the American ...
... from Phase III clinical trial --, CHICAGO, ... today announced the presentation of updated results from,a ... comparing,VELCADE and dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone ... of,19 percent in the VcD arm as induction ...
Cached Medicine Technology:Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 2Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 3Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 4Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Insurance Group, Inc. has re-branded their social media profiles to better connect with ... for consumers to communicate, find information, share insights and opinions. The Rally Insurance ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... ranging from crushing depression and crippling anxiety to powerful delusions ... real from the imagined. And if that weren,t enough, ... of the world perceives their inner struggle. Stigma ...
... , THURSDAY, Dec. 29 (HealthDay News) -- Individuals may ... if they carry abnormalities in the so-called "ATM" gene, ... upcoming issue of Cancer Discovery , stems from ... comparative purposes, 190 other individuals who did not have ...
... Dec. 29, 2011--Dr. Andrew Advani, an endocrinologist at St. ... America who received a newly created Novo Nordisk Diabetes ... worth $325,000 (U.S.) over two years. His research ... in patients suffering from diabetes. In diabetic kidney disease, ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) ... and vitamins B, C, D and E in their blood ... tended to have larger brain volume, a new study finds. ... blood fared worse on certain thinking tests than those with ...
... Disease-causing strains of the fungus Fusarium are present ... of infection in humans, according to a new study. ... agricultural crops, but some species of the fungus can cause ... example, Fusarium was the cause of an outbreak ...
... crystal-clear tunes at high volume for hours on end ... according to Tel Aviv University research, these advances have also ... teenagers as the most at-risk group. One ... as a direct result of these listening habits, says Prof. ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:Gene Mutation May Be Key to Familial Pancreatic Cancer 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 3Health News:Fungus Found in Sinks Can Cause Serious Infections 2Health News:Turn down the iPod to save your hearing 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: